Medicines
Find Medicines
Search 21,000+ medicines by brand, generic, indication, or drug class
GastroLax
Ispaghula Husk + Ispaghula Seed + Tinnevelly Senna Pods
GastroLax
Ispaghula Husk + Ispaghula Seed + Tinnevelly Senna Pods
Indications
Constipation
Indication detailsView
This is indicated in constipation.
Therapeutic classView
Bulk-forming laxatives
Gastroaid
Fermented soy [Lactobacillus Delbrueckii]
Gastroaid
Fermented soy [Lactobacillus Delbrueckii]
Indications
Nausea
Indication detailsView
- Acute and chronic gastritis
- Digestive disorders like Anorexia, Nausea and Constipation
- Occasional heartburn
- Gastric and duodenal ulcers
Therapeutic classView
Herbal and Nutraceuticals
PharmacologyView
Fermented soy is a natural medicine produced from fermented soybeans by specific strain Lactobacillus delbrueckii. It helps to support the digestive system and eases the occasional discomfort associated with sour stomach. Bioactive compounds of fermented soy is useful in gastric discomfort management and quick relief of gastric discomfort. Fermented soy enhances appetite, relieves nausea, vomiting & gastric acid reflux.
It also repairs gastric mucosa and reduces the incidence of stomach inflammation. Fermented soy has buffering effect on the stomach pH due to high concentration of proteins or metabolites. Fermented soy releases anti-nutritional peptides that inhibit the action of the protease enzymes on stomach lining, thus protecting gastric epithelium. It also has an down-regulating effect on the expression of pro-inflammatory cytokines that helps in the healing process of gastric ulceration. Fermented soy is also designed to address the discomfort of occasional indigestion.
It also repairs gastric mucosa and reduces the incidence of stomach inflammation. Fermented soy has buffering effect on the stomach pH due to high concentration of proteins or metabolites. Fermented soy releases anti-nutritional peptides that inhibit the action of the protease enzymes on stomach lining, thus protecting gastric epithelium. It also has an down-regulating effect on the expression of pro-inflammatory cytokines that helps in the healing process of gastric ulceration. Fermented soy is also designed to address the discomfort of occasional indigestion.
DosageView
Generally 1-2 tablets three times a day before meals or as advised by the physician.
Side effectsView
Well tolerated in recommended dose
ContraindicationsView
Known hypersensitivity to any of its active ingredients
PrecautionsView
Store at temperature of below 30˚C, protect from light & moisture. Keep out of reach of children.
InteractionsView
Possible drug interaction is present with mono-amine oxidase inhibitors a medication use in depression.
Pregnancy & lactationView
Sufficient clinical data are not available for using in pregnant and lactating women.
Gastrocon
Sodium Alginate + Potassium Bicarbonate
Gastrocon
Sodium Alginate + Potassium Bicarbonate
Indication detailsView
This preparation is indicated for the treatment of symptoms resulting from the reflux of acid, bile and pepsin into the esophagus such as acid regurgitation, heartburn, indigestion for instance, after gastric surgery, as a result of hiatus hernia, during pregnancy, accompanying reflux esophagitis, including symptoms of laryngopharyngeal reflux such as hoarseness and other voice disorders, sore throats and cough. This preparation can also be used to treat the symptoms of gastroesophageal reflux during concomitant treatment with or following the withdrawal of acid suppressing therapy.
Therapeutic classView
Antacids
PharmacologyView
This is the combination of Sodium Alginate and Potassium Bicarbonate. Sodium Alginate is a naturally occurring substance. It reacts with the acid in the stomach to form a gel. Potassium Bicarbonate also reacts with the acid in the stomach to form bubbles of carbon dioxide. These bubbles are trapped by the gel formed by Sodium Alginate and they allow the gel to float like a raft on top of the stomach contents. The raft prevents acid in the stomach from flowing back into the esophagus. This relieves the symptoms of reflux such as heartburn. The mode of action of this is physical and does not depend on absorption into the systemic circulation. The raft lasts for up to 4 hours on top of the stomach contents and is then broken down in the digestive system and excreted in the feces.
DosageView
Tablet:
Elderly: No dose modifications are necessary for this age group.
Hepatic Impairment: No dose modifications are necessary.
Renal Insufficiency: Caution if a highly restricted salt diet is necessary.
- Adults and children over 12 years: 1-2 tablets 3-4 times daily, after meals and before bedtime.
- Children 6-12 years: ½-1 tablet 3-4 times daily, after meals and before bedtime.
- Adults and children 12 years and above: 5-10 ml (1-2 teaspoonfuls) 3-4 times daily, after meals and before bedtime.
- Children 2-12 years: 2.5-5ml (½-1 teaspoonful) 3-4 times daily, after meals and before bedtime.
Elderly: No dose modifications are necessary for this age group.
Hepatic Impairment: No dose modifications are necessary.
Renal Insufficiency: Caution if a highly restricted salt diet is necessary.
Side effectsView
In addition to the desired effect of the drug, some side effects may appear such as: nausea, constipation, diarrhea or headache. In these cases consult a physician In case too big dosage has been taken, there might appear a sensation of swelling. In this case it is advisable to consult a physician.
ContraindicationsView
Sodium alginate and potassium bicarbonate is contraindicated in patients with known hypersensitivity to these.
PrecautionsView
Sodium Alginate and Potassium Bicarbonate should be prescribed with caution in patients with renal impairment and congestive cardiac failure. Care needs to be taken in treating patients with hypercalcemia, nephrocalcinosis and recurrent calcium-containing renal calculi. There is a possibility of reduced efficacy in patients with very low levels of gastric acid. If symptoms do not improve after seven days, the clinical situation should be reviewed.
InteractionsView
A time interval of 2 hours should be considered between this intake and the administration of other medicinal products, especially tetracyclines, fluoroquinolones, iron salts, thyroid hormones, chloroquine, bisphosphonates, and estramustine.
Pregnancy & lactationView
This combination (Sodium Alginate and Potassium Bicarbonate) can be used during pregnancy, if clinically needed. No known effect on breast-fed infants. This combination can be used during breastfeeding.
Overdose effectsView
Overdosage with this formulation is a rare case. In case of overdose please consult with a registered physician.
StorageView
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
Gastrocon
Sodium Alginate + Potassium Bicarbonate
Gastrocon
Sodium Alginate + Potassium Bicarbonate
Indication detailsView
This preparation is indicated for the treatment of symptoms resulting from the reflux of acid, bile and pepsin into the esophagus such as acid regurgitation, heartburn, indigestion for instance, after gastric surgery, as a result of hiatus hernia, during pregnancy, accompanying reflux esophagitis, including symptoms of laryngopharyngeal reflux such as hoarseness and other voice disorders, sore throats and cough. This preparation can also be used to treat the symptoms of gastroesophageal reflux during concomitant treatment with or following the withdrawal of acid suppressing therapy.
Therapeutic classView
Antacids
PharmacologyView
This is the combination of Sodium Alginate and Potassium Bicarbonate. Sodium Alginate is a naturally occurring substance. It reacts with the acid in the stomach to form a gel. Potassium Bicarbonate also reacts with the acid in the stomach to form bubbles of carbon dioxide. These bubbles are trapped by the gel formed by Sodium Alginate and they allow the gel to float like a raft on top of the stomach contents. The raft prevents acid in the stomach from flowing back into the esophagus. This relieves the symptoms of reflux such as heartburn. The mode of action of this is physical and does not depend on absorption into the systemic circulation. The raft lasts for up to 4 hours on top of the stomach contents and is then broken down in the digestive system and excreted in the feces.
DosageView
Tablet:
Elderly: No dose modifications are necessary for this age group.
Hepatic Impairment: No dose modifications are necessary.
Renal Insufficiency: Caution if a highly restricted salt diet is necessary.
- Adults and children over 12 years: 1-2 tablets 3-4 times daily, after meals and before bedtime.
- Children 6-12 years: ½-1 tablet 3-4 times daily, after meals and before bedtime.
- Adults and children 12 years and above: 5-10 ml (1-2 teaspoonfuls) 3-4 times daily, after meals and before bedtime.
- Children 2-12 years: 2.5-5ml (½-1 teaspoonful) 3-4 times daily, after meals and before bedtime.
Elderly: No dose modifications are necessary for this age group.
Hepatic Impairment: No dose modifications are necessary.
Renal Insufficiency: Caution if a highly restricted salt diet is necessary.
Side effectsView
In addition to the desired effect of the drug, some side effects may appear such as: nausea, constipation, diarrhea or headache. In these cases consult a physician In case too big dosage has been taken, there might appear a sensation of swelling. In this case it is advisable to consult a physician.
ContraindicationsView
Sodium alginate and potassium bicarbonate is contraindicated in patients with known hypersensitivity to these.
PrecautionsView
Sodium Alginate and Potassium Bicarbonate should be prescribed with caution in patients with renal impairment and congestive cardiac failure. Care needs to be taken in treating patients with hypercalcemia, nephrocalcinosis and recurrent calcium-containing renal calculi. There is a possibility of reduced efficacy in patients with very low levels of gastric acid. If symptoms do not improve after seven days, the clinical situation should be reviewed.
InteractionsView
A time interval of 2 hours should be considered between this intake and the administration of other medicinal products, especially tetracyclines, fluoroquinolones, iron salts, thyroid hormones, chloroquine, bisphosphonates, and estramustine.
Pregnancy & lactationView
This combination (Sodium Alginate and Potassium Bicarbonate) can be used during pregnancy, if clinically needed. No known effect on breast-fed infants. This combination can be used during breastfeeding.
Overdose effectsView
Overdosage with this formulation is a rare case. In case of overdose please consult with a registered physician.
StorageView
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
Gastrocon-A
Sodium Alginate + Potassium Bicarbonate
Gastrocon-A
Sodium Alginate + Potassium Bicarbonate
Indication detailsView
This preparation is indicated for the treatment of symptoms resulting from the reflux of acid, bile and pepsin into the esophagus such as acid regurgitation, heartburn, indigestion for instance, after gastric surgery, as a result of hiatus hernia, during pregnancy, accompanying reflux esophagitis, including symptoms of laryngopharyngeal reflux such as hoarseness and other voice disorders, sore throats and cough. This preparation can also be used to treat the symptoms of gastroesophageal reflux during concomitant treatment with or following the withdrawal of acid suppressing therapy.
Therapeutic classView
Antacids
PharmacologyView
This is the combination of Sodium Alginate and Potassium Bicarbonate. Sodium Alginate is a naturally occurring substance. It reacts with the acid in the stomach to form a gel. Potassium Bicarbonate also reacts with the acid in the stomach to form bubbles of carbon dioxide. These bubbles are trapped by the gel formed by Sodium Alginate and they allow the gel to float like a raft on top of the stomach contents. The raft prevents acid in the stomach from flowing back into the esophagus. This relieves the symptoms of reflux such as heartburn. The mode of action of this is physical and does not depend on absorption into the systemic circulation. The raft lasts for up to 4 hours on top of the stomach contents and is then broken down in the digestive system and excreted in the feces.
DosageView
Tablet:
Elderly: No dose modifications are necessary for this age group.
Hepatic Impairment: No dose modifications are necessary.
Renal Insufficiency: Caution if a highly restricted salt diet is necessary.
- Adults and children over 12 years: 1-2 tablets 3-4 times daily, after meals and before bedtime.
- Children 6-12 years: ½-1 tablet 3-4 times daily, after meals and before bedtime.
- Adults and children 12 years and above: 5-10 ml (1-2 teaspoonfuls) 3-4 times daily, after meals and before bedtime.
- Children 2-12 years: 2.5-5ml (½-1 teaspoonful) 3-4 times daily, after meals and before bedtime.
Elderly: No dose modifications are necessary for this age group.
Hepatic Impairment: No dose modifications are necessary.
Renal Insufficiency: Caution if a highly restricted salt diet is necessary.
Side effectsView
In addition to the desired effect of the drug, some side effects may appear such as: nausea, constipation, diarrhea or headache. In these cases consult a physician In case too big dosage has been taken, there might appear a sensation of swelling. In this case it is advisable to consult a physician.
ContraindicationsView
Sodium alginate and potassium bicarbonate is contraindicated in patients with known hypersensitivity to these.
PrecautionsView
Sodium Alginate and Potassium Bicarbonate should be prescribed with caution in patients with renal impairment and congestive cardiac failure. Care needs to be taken in treating patients with hypercalcemia, nephrocalcinosis and recurrent calcium-containing renal calculi. There is a possibility of reduced efficacy in patients with very low levels of gastric acid. If symptoms do not improve after seven days, the clinical situation should be reviewed.
InteractionsView
A time interval of 2 hours should be considered between this intake and the administration of other medicinal products, especially tetracyclines, fluoroquinolones, iron salts, thyroid hormones, chloroquine, bisphosphonates, and estramustine.
Pregnancy & lactationView
This combination (Sodium Alginate and Potassium Bicarbonate) can be used during pregnancy, if clinically needed. No known effect on breast-fed infants. This combination can be used during breastfeeding.
Overdose effectsView
Overdosage with this formulation is a rare case. In case of overdose please consult with a registered physician.
StorageView
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
Gastrocon-A
Sodium Alginate + Potassium Bicarbonate
Gastrocon-A
Sodium Alginate + Potassium Bicarbonate
Indication detailsView
This preparation is indicated for the treatment of symptoms resulting from the reflux of acid, bile and pepsin into the esophagus such as acid regurgitation, heartburn, indigestion for instance, after gastric surgery, as a result of hiatus hernia, during pregnancy, accompanying reflux esophagitis, including symptoms of laryngopharyngeal reflux such as hoarseness and other voice disorders, sore throats and cough. This preparation can also be used to treat the symptoms of gastroesophageal reflux during concomitant treatment with or following the withdrawal of acid suppressing therapy.
Therapeutic classView
Antacids
PharmacologyView
This is the combination of Sodium Alginate and Potassium Bicarbonate. Sodium Alginate is a naturally occurring substance. It reacts with the acid in the stomach to form a gel. Potassium Bicarbonate also reacts with the acid in the stomach to form bubbles of carbon dioxide. These bubbles are trapped by the gel formed by Sodium Alginate and they allow the gel to float like a raft on top of the stomach contents. The raft prevents acid in the stomach from flowing back into the esophagus. This relieves the symptoms of reflux such as heartburn. The mode of action of this is physical and does not depend on absorption into the systemic circulation. The raft lasts for up to 4 hours on top of the stomach contents and is then broken down in the digestive system and excreted in the feces.
DosageView
Tablet:
Elderly: No dose modifications are necessary for this age group.
Hepatic Impairment: No dose modifications are necessary.
Renal Insufficiency: Caution if a highly restricted salt diet is necessary.
- Adults and children over 12 years: 1-2 tablets 3-4 times daily, after meals and before bedtime.
- Children 6-12 years: ½-1 tablet 3-4 times daily, after meals and before bedtime.
- Adults and children 12 years and above: 5-10 ml (1-2 teaspoonfuls) 3-4 times daily, after meals and before bedtime.
- Children 2-12 years: 2.5-5ml (½-1 teaspoonful) 3-4 times daily, after meals and before bedtime.
Elderly: No dose modifications are necessary for this age group.
Hepatic Impairment: No dose modifications are necessary.
Renal Insufficiency: Caution if a highly restricted salt diet is necessary.
Side effectsView
In addition to the desired effect of the drug, some side effects may appear such as: nausea, constipation, diarrhea or headache. In these cases consult a physician In case too big dosage has been taken, there might appear a sensation of swelling. In this case it is advisable to consult a physician.
ContraindicationsView
Sodium alginate and potassium bicarbonate is contraindicated in patients with known hypersensitivity to these.
PrecautionsView
Sodium Alginate and Potassium Bicarbonate should be prescribed with caution in patients with renal impairment and congestive cardiac failure. Care needs to be taken in treating patients with hypercalcemia, nephrocalcinosis and recurrent calcium-containing renal calculi. There is a possibility of reduced efficacy in patients with very low levels of gastric acid. If symptoms do not improve after seven days, the clinical situation should be reviewed.
InteractionsView
A time interval of 2 hours should be considered between this intake and the administration of other medicinal products, especially tetracyclines, fluoroquinolones, iron salts, thyroid hormones, chloroquine, bisphosphonates, and estramustine.
Pregnancy & lactationView
This combination (Sodium Alginate and Potassium Bicarbonate) can be used during pregnancy, if clinically needed. No known effect on breast-fed infants. This combination can be used during breastfeeding.
Overdose effectsView
Overdosage with this formulation is a rare case. In case of overdose please consult with a registered physician.
StorageView
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
Gastrocon-DA
Sodium Alginate + Sodium Bicarbonate + Calcium Carbonate
Gastrocon-DA
Sodium Alginate + Sodium Bicarbonate + Calcium Carbonate
Indication detailsView
This preparation is indicated in Gastric reflux, Heartburn, Flatulence associated with gastric reflux, Heartburn of pregnancy, All cases of epigastric and retrosternal distress where the underlying cause is gastric reflux.
Therapeutic classView
Antacids
PharmacologyView
The mode of action of the product is physical and does not depend on absorption into the systemic circulation. On ingestion, the product reacts rapidly with gastric acid to form a raft of Alginic acid gel having a near-neutral pH and which floats on the stomach contents quickly and effectively impeding gastro-esophageal reflux, for up to 4 hours. In severe cases, the raft itself may be refluxed into the esophagus in preference to the stomach contents and exert a demulcent effect.
DosageView
For oral administration:
Adult and children over 12 years:10-20 mL after meals and at bedtime, up to four times a day.
Children 6 to 12 years: 5-10 mL after meals and at bedtime, up to four times a day.
Children under 6 years: Not recommended.
Elderly: No dosage modification is required for this age group.
Adult and children over 12 years:10-20 mL after meals and at bedtime, up to four times a day.
Children 6 to 12 years: 5-10 mL after meals and at bedtime, up to four times a day.
Children under 6 years: Not recommended.
Elderly: No dosage modification is required for this age group.
Side effectsView
In addition to the desired effect of the drug, some side effects may appear such as: constipation, flatulence, stomach cramp or belching. In these cases consult a physician. If too big dose has been taken, there might appear a sensation of swelling. In this case, it is advisable to consult a physician.
ContraindicationsView
This product is contraindicated in patients with known or suspected hypersensitivity to the active ingredients or to any of the excipients.
PrecautionsView
If symptoms do not improve after 7 days, the clinical situation should be reviewed. Each 10 mL dose has a Sodium content of 141 mg (6.2 mmoL). This should be taken into account when a highly restricted salt diet is recommended, e.g. in some cases of congestive cardiac failure and renal impairment. Each 10 mL dose contains 160 mg (1.6 mmoL) of Calcium Carbonate. Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi.
InteractionsView
A time-interval of 2 hours should be considered between this drug intake and the administration of other medicinal products, especially Tetracyclines, Digoxine, Fluoroquinolone, Iron salt, Ketoconazole, Neuroleptics, Thyroid Hormones, Penicillamine, beta-blockers (Atenolol, Metoprolol, Propranolol), Glucocorticoid, Chloroquine and Biphosphonates (diphosphonates) and Estramustine.
Pregnancy & lactationView
Pregnancy: Clinical studies in more than 500 pregnant women, as well as a large amount of data from post-marketing experience, indicate no malformative nor feto/neonatal toxicity of the active ingredients. This drug can be used during pregnancy, if clinically needed.
Breastfeeding: No effects of the active substances have been shown in breastfed newborns/infants of treated mothers. This drug can be used during breastfeeding.
Fertility: Pre-clinical investigations have revealed Alginate has no negative effect on parental or offspring fertility or reproduction. Clinical data do not suggest that this drug has an effect on human fertility.
Breastfeeding: No effects of the active substances have been shown in breastfed newborns/infants of treated mothers. This drug can be used during breastfeeding.
Fertility: Pre-clinical investigations have revealed Alginate has no negative effect on parental or offspring fertility or reproduction. Clinical data do not suggest that this drug has an effect on human fertility.
Overdose effectsView
In the event of over dosage symptomatic treatment should be given. The patient may notice abdominal distension.
StorageView
Store in a cool (below 30°C) and dry place, away from light. Keep out of the reach of children. Do not refrigerate or freeze.
Gastrocon-R
Sodium Alginate + Sodium Bicarbonate + Calcium Carbonate
Gastrocon-R
Sodium Alginate + Sodium Bicarbonate + Calcium Carbonate
Indication detailsView
This preparation is indicated in Gastric reflux, Heartburn, Flatulence associated with gastric reflux, Heartburn of pregnancy, All cases of epigastric and retrosternal distress where the underlying cause is gastric reflux.
Therapeutic classView
Antacids
PharmacologyView
The mode of action of the product is physical and does not depend on absorption into the systemic circulation. On ingestion, the product reacts rapidly with gastric acid to form a raft of Alginic acid gel having a near-neutral pH and which floats on the stomach contents quickly and effectively impeding gastro-esophageal reflux, for up to 4 hours. In severe cases, the raft itself may be refluxed into the esophagus in preference to the stomach contents and exert a demulcent effect.
DosageView
For oral administration:
Adult and children over 12 years:10-20 mL after meals and at bedtime, up to four times a day.
Children 6 to 12 years: 5-10 mL after meals and at bedtime, up to four times a day.
Children under 6 years: Not recommended.
Elderly: No dosage modification is required for this age group.
Adult and children over 12 years:10-20 mL after meals and at bedtime, up to four times a day.
Children 6 to 12 years: 5-10 mL after meals and at bedtime, up to four times a day.
Children under 6 years: Not recommended.
Elderly: No dosage modification is required for this age group.
Side effectsView
In addition to the desired effect of the drug, some side effects may appear such as: constipation, flatulence, stomach cramp or belching. In these cases consult a physician. If too big dose has been taken, there might appear a sensation of swelling. In this case, it is advisable to consult a physician.
ContraindicationsView
This product is contraindicated in patients with known or suspected hypersensitivity to the active ingredients or to any of the excipients.
PrecautionsView
If symptoms do not improve after 7 days, the clinical situation should be reviewed. Each 10 mL dose has a Sodium content of 141 mg (6.2 mmoL). This should be taken into account when a highly restricted salt diet is recommended, e.g. in some cases of congestive cardiac failure and renal impairment. Each 10 mL dose contains 160 mg (1.6 mmoL) of Calcium Carbonate. Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi.
InteractionsView
A time-interval of 2 hours should be considered between this drug intake and the administration of other medicinal products, especially Tetracyclines, Digoxine, Fluoroquinolone, Iron salt, Ketoconazole, Neuroleptics, Thyroid Hormones, Penicillamine, beta-blockers (Atenolol, Metoprolol, Propranolol), Glucocorticoid, Chloroquine and Biphosphonates (diphosphonates) and Estramustine.
Pregnancy & lactationView
Pregnancy: Clinical studies in more than 500 pregnant women, as well as a large amount of data from post-marketing experience, indicate no malformative nor feto/neonatal toxicity of the active ingredients. This drug can be used during pregnancy, if clinically needed.
Breastfeeding: No effects of the active substances have been shown in breastfed newborns/infants of treated mothers. This drug can be used during breastfeeding.
Fertility: Pre-clinical investigations have revealed Alginate has no negative effect on parental or offspring fertility or reproduction. Clinical data do not suggest that this drug has an effect on human fertility.
Breastfeeding: No effects of the active substances have been shown in breastfed newborns/infants of treated mothers. This drug can be used during breastfeeding.
Fertility: Pre-clinical investigations have revealed Alginate has no negative effect on parental or offspring fertility or reproduction. Clinical data do not suggest that this drug has an effect on human fertility.
Overdose effectsView
In the event of over dosage symptomatic treatment should be given. The patient may notice abdominal distension.
StorageView
Store in a cool (below 30°C) and dry place, away from light. Keep out of the reach of children. Do not refrigerate or freeze.
Gastroloc
Ranitidine Hydrochloride
Gastroloc
Ranitidine Hydrochloride
Indications
Zollinger-Ellison syndrome
Indication detailsView
Ranitidine is indicated in:
- Treatment of active duodenal ulcer
- Benign gastric ulcer
- Treatment & prevention of ulcer associated with non-steroidal anti-inflammatory agent
- Post operative stress ulcer.
- Zollinger-Ellison Syndrome.
- Gastroesophageal reflux disease (GERD).
- Gastro-intestinal haemorrhage from stress ulcer in seriously ill patient.
- Recurrent haemorrhage in patients with bleeding peptic ulcer.
- Before general anesthesia in patient considered to be at risk of acid aspiration particulary obstetric patients.
Therapeutic classView
H2 receptor antagonist
PharmacologyView
Ranitidine competitively blocks histamine at H2-receptors of the gastric parietal cells which inhibits gastric acid secretion. It does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion or serum gastrin.
DosageView
Ranitidine Tablet & Syrup:
Duodenal and gastric ulcer: The usual dosage is 150 mg twice daily taken in the morning and evening or 300 mg as a single daily dose at night for 4 to 8 weeks.Reflux oesophagitis: 150 mg twice daily or 300 mg at bed time for up to 8 weeks.
Zollinger Ellison syndrome: 150 mg 3 times daily and increased if necessary up to 6 g daily in divided doses. Dosage should be continued as long as clinically indicated.
Episodic dyspepsia: 150 mg twice daily or 300 mg at bed time for up to 6 weeks.
Maintenance: 150 mg at night for preventing recurrences.
Child (peptic ulcer): 2-4 mg/kg twice daily, maximum 300 mg daily.
Ranitidine IV injection & IV Infusion:
Ranitidine injection may be given either as a slow (over a period of at least two minutes) intravenous injection of 50 mg, after dilution to a volume of 20 ml per 50 mg dose, which may be repeated every six to eight hours; or as an intermittent intravenous infusion at a rate of 25 mg per hour for two hours; the infusion may be repeated at six to eight hour intervals; or as an intramuscular injection of 50 mg (2 ml) every six to eight hours. In the prophylaxis of haemorrhage from stress ulceration in seriously ill patients or the prophylaxis of recurrent haemorrhage in patients bleeding from peptic ulceration, parenteral administration may be continued until oral feeding commences.In the prophylaxis of upper gastrointestinal haemorrhage from stress ulceration in seriously ill patient sapriming dose of 50 mg as low as intravenous injection followed by a continuous intravenous infusion of 0.125-0.250 mg/kg/hour may be preferred. In patients considered to be at risk of developing aspiration syndrome Ranitidine injection 50 mg may be given intramuscularly or by slow intravenous injection 45 to 60 minutes before induction of general anaesthesia.
Children: The recommended oral dose for the treatment of peptic ulcer in children is 2 mg/kg to 4 mg/kg twice daily to a maximum of 300 mg ranitidine per day. Safety and effectiveness of Ranitidine injection have not been established in case of children.
Side effectsView
Ranitidine is well tolerated and side effects are usually uncommon. Altered bowel habit, dizziness, rash, tiredness, reversible confusional states, headache, decreased blood counts, muscle or joint pain have rarely been reported.
ContraindicationsView
Patients hypersensitive to Ranitidine
PrecautionsView
Ranitidine should be given in reduced dosage to patients with impaired renal and hepatic function.
InteractionsView
Delayed absorption and increased peak serum concentration with propantheline bromide. Ranitidine minimally inhibits hepatic metabolism of coumarin anticoagulants, theophylline, diazepam and propanolol. May alter absorption of pH-dependent drugs (e.g. ketoconazole, midazolam, glipizide). May reduce bioavailability with antacids.
Pregnancy & lactationView
Pregnancy: Ranitidine crosses the placenta. But there is no evidence of impaired fertility or harm to the foetus due to Ranitidine. Like other drugs, Ranitidine should only be used during pregnancy if considered essential.
Lactation: Ranitidine is excreted in human breast milk. Caution should be exercised when the drug is administered to a nursing mother.
Lactation: Ranitidine is excreted in human breast milk. Caution should be exercised when the drug is administered to a nursing mother.
Pediatric usageView
Use in elderly patients: In clinical trial the ulcer healing rates have been found similar in patients age 65 and over with those in younger patients. Additionally, there was no difference in the incidence of adverse effects.
Overdose effectsView
Ranitidine is very specific in action and accordingly no particular problems are expected following overdosage with the drug. Symptomatic and supportive therapy should be given as appropriate. If required, the drug may be removed from the plasma by haemodiaiysis.
ReconstitutionView
Slow IV inj: Ranitidine 50 mg diluted to a concentration ≤2.5 mg/mL (e.g. total of 20 mL) with NaCl 0.9% inj or dextrose 5% or 10%, lactated Ringer's, Na bicarbonate 5% soln.
Intermittent slow IV infusion: Ranitidine 50 mg diluted to a concentration ≤0.5 mg/mL (e.g. total of 100 mL) of dextrose 5% inj or NaCl 0.9%, lactated Ringer's, Na bicarbonate 5% soln.
Continuous IV infusion: Ranitidine 150 mg diluted in 250 mL of dextrose 5% inj or NaCl 0.9%, lactated Ringer's, Na bicarbonate 5% soln.
Patients with Zollinger-Ellison syndrome or other hypersecretory conditions: Ranitidine should be diluted to a concentration ≤2.5 mg/mL with dextrose 5% or NaCl 0.9%, lactated Ringer's, Na bicarbonate 5% soln.
Intermittent slow IV infusion: Ranitidine 50 mg diluted to a concentration ≤0.5 mg/mL (e.g. total of 100 mL) of dextrose 5% inj or NaCl 0.9%, lactated Ringer's, Na bicarbonate 5% soln.
Continuous IV infusion: Ranitidine 150 mg diluted in 250 mL of dextrose 5% inj or NaCl 0.9%, lactated Ringer's, Na bicarbonate 5% soln.
Patients with Zollinger-Ellison syndrome or other hypersecretory conditions: Ranitidine should be diluted to a concentration ≤2.5 mg/mL with dextrose 5% or NaCl 0.9%, lactated Ringer's, Na bicarbonate 5% soln.
StorageView
Store in a cool and dry place. protect from light.
Gatibac
Gatifloxacin (Ophthalmic)
Gatibac
Gatifloxacin (Ophthalmic)
Indications
Inflammation of the cornea
Indication detailsView
Gatifloxacin eye drops is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:
- Aerobic Gram-Positive Bacteria: Corynebacterium propinquum, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mitis, Streptococcus pneumoniae
- Aerobic Gram-Negative Bacteria: Haemophilus influenzae.
Therapeutic classView
Ophthalmic antibacterial drugs
PharmacologyView
The antibacterial action of gatifloxacin results from inhibition of DNA gyrase and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division. The mechanism of action of fluoroquinolones including gatifloxacin is different from that of aminoglycoside, macrolide, and tetracycline antibiotics. Therefore, gatifloxacin may be active against pathogens that are resistant to these antibiotics and these antibiotics may be active against pathogens that are resistant to gatifloxacin. There is no crossresistance between gatifloxacin and the aforementioned classes of antibiotics. Cross resistance has been observed between systemic gatifloxacin and some other fluoroquinolones. Resistance to gatifloxacin in vitro develops via multiple-step mutations.
DosageView
0.3% eye drops-
The recommended dosage regimen for the treatment of bacterial conjunctivitis is:- Days 1 and 2: Instill one drop every two hours in the affected eye(s) while awake, up to 8 times daily.
- Days 3 through 7: Instill one drop up to 4 times daily while awake.
0.5% eye drops-
Patients 1 year of age or older: Instill one drop every two hours in the affected eye(s) while awake, up to 8 times on Day 1. Instill one drop two to four times daily in the affected eye(s) while awake on Days 2 through 7.Side effectsView
The most frequently reported adverse events in the overall study population were conjunctival irritation, increased lacrimation etc.
ContraindicationsView
Gatifloxacin eye drops is contraindicated in patients with a history of hypersensitivity to Gatifloxacin, to other quinolones, or to any of the components in this medication. Gatiflox 0.3% eye drops should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye.
PrecautionsView
Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial conjunctivitis. Avoid contaminating the applicator tip with material from the eye, fingers or other source.
InteractionsView
Specific drug interaction studies have not been conducted with gatifloxacin eye drops. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.
Pregnancy & lactationView
Pregnancy Category C. Because there are no adequate and well-controlled studies in pregnant women, Gatifloxacin 0.3% eye drops should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Gatifloxacin is administered to a nursing woman.
Lactation: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Gatifloxacin is administered to a nursing woman.
Pediatric usageView
Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger patients.
Overdose effectsView
An overdose of this medication is unlikely to threaten life.
StorageView
Store in a cool and dry place, away from light. Keep out of reach of children.
Gaticin
Gatifloxacin (Oral)
Gaticin
Gatifloxacin (Oral)
Indications
Urinary tract infection
Indication detailsView
Gatifloxacin is indicated in the following infections:
- Acute bacterial exacerbation of chronic bronchitis due to Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Staphylococcus aureus.
- Acute sinusitis due to Streptococcus pneumoniae or Haemophilus influenzae.
- Community-acquired pneumonia due to Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Staphylococcus aureus, Mycoplasma pneumoniae, Chlamydia pneumoniae, or Legionella pneumophila.
- Uncomplicated skin and skin structure infections (i.e., simple abscesses, furuncles, folliculitis, wound infections, and cellulitis) due to Staphylococcus aureus or Streptococcus pyogenes.
- Uncomplicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis.
- Complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis.
- Pyelonephritis due to Escherichia coli.
- Uncomplicated urethral and cervical gonorrhea due to Neisseria gonorrhoeae.
- Acute, uncomplicated rectal infections in women due to Neisseria gonorrhoeae.
Therapeutic classView
4-Quinolone preparations
PharmacologyView
Gatifloxacin is a fluoroquinolone antibacterial which acts by inhibiting DNA synthesis in susceptible organisms via inhibition of both DNA gyrase (essential for bacterial reproduction) and topoisomerase IV (essential during bacterial cell division).
DosageView
- Acute Bacterial Exacerbation of Chronic Bronchitis: 400 mg 5 days
- Acute Sinusitis: 400 mg 10 days
- Community-acquired Pneumonia: 400 mg 7-14 days
- Uncomplicated Skin and Skin Structure Infections: 400 mg 7-10 days
- Uncomplicated Urinary Tract Infections: 400 mg Single Dose or 200 mg 3 days
- Complicated Urinary Tract Infections: 400 mg 7-10 days
- Acute Pyelonephritis: 400 mg 7-10 days
- Uncomplicated Urethral Gonnorrhea in Men: 400 mg Single dose
AdministrationView
Gatifloxacin can be administered without regard to food.
Side effectsView
Gatifloxacin is generally well tolerated. The most common side effects that can occur while taking this drug are usually mild and include nausea, vomiting, stomach pain, diarrhea, dizziness,and headache .
ContraindicationsView
Gatifloxacin is contraindicated in patients with a history of hypersensitivity of Gatifloxacin, quinolone antimicrobial agents, or any other components of this product.
PrecautionsView
Gatifloxacin should be administered with caution in the presence of renal insufficiency.
Pregnancy & lactationView
Pregnancy: Gatifloxacin should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus.
Lactation: It is not known whether Gatifloxacin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when gatifloxacin is administered to a nursing woman.
Lactation: It is not known whether Gatifloxacin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when gatifloxacin is administered to a nursing woman.
Pediatric usageView
Renal Impaired patient:
- Creatinine Clearance 40 mL/min: 400 mg every day.
- Creatinine Clearance < 40 mL/min: 400 mg 200 mg every day.
- Hemodialysis: 400 mg 200 mg every day.
- Continuous peritoneal dialysis: 400 mg 200 mg every day.
Overdose effectsView
Gatifloxacin exhibits a low potential for acute toxicity in animal studies. In the event of acute oral overdose, the stomach should be emptied by inducing vomiting or by gastric lavage. The patient should be carefully observed (including ECG monitoring) and given symptomatic and supportive treatment. Adequate hydration should be maintained.
Gatidex
Gatifloxacin + Dexamethasone
Gatidex
Gatifloxacin + Dexamethasone
Indications
Steroid-responsive inflammatory ocular conditions
Indication detailsView
This Sterile Eye Drops is indicated for steroid responsive ocular inflammatory conditions with involvement of bacteria like blepharitis, scleritis, episcleritis, iritis, cyclitis, iridocyclitis, choroiditis, optic neuritis and chronic anterior uveitis, disciform and interstitial keratitis, allergic corneal marginal ulcers, corneal injury from chemical radiation or thermal burns.
Therapeutic classView
Ophthalmic steroid - antibiotic combined preparations
PharmacologyView
Dexamethasone is a synthetic glucocorticoid which decreases inflammation by inhibiting the migration of leukocytes and reversal of increased capillary permeability. It suppresses normal immune response.
Gatifloxacin inhibits bacterial DNA gyrase and Topoisomerase IV, the enzymes responsible for replication, transcription and repair of bacterial DNA.
Gatifloxacin inhibits bacterial DNA gyrase and Topoisomerase IV, the enzymes responsible for replication, transcription and repair of bacterial DNA.
DosageView
Instill 1-2 drops into the conjunctival sac 3 to 4 times daily.
Side effectsView
Mild burning, chemosis, redness may occur.
ContraindicationsView
This is contraindicated in epithelial herpes simplex keratitis (Dendritic keratitis), vaccinia, varicella, and in many other viral diseases of the conjunctiva and cornea. It is also contraindicated in mycobacterial infection of the eye, fungal diseases of ocular structures and in individuals hypersensitive to any of the components of the medication.
PrecautionsView
For ophthalmic use only. If the product is used for 10 days or more, intraocular pressure should be monitored routinely.
Pregnancy & lactationView
Use in pregnancy: There are no adequate and well-controlled studies in pregnant women. Gatifloxacin + Dexamethasone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Use in lactation: Caution should be exercised when Gatifloxacin + Dexamethasone is administered to a nursing mother.
Use in lactation: Caution should be exercised when Gatifloxacin + Dexamethasone is administered to a nursing mother.
Pediatric usageView
Use in children: Safety and effectiveness in pediatric patients have not been established.
Overdose effectsView
Overdose through local administration is not known. In case of accidental oral intake, specific measures to reduce resorption should be taken. There is no specific antidote.
StorageView
Store at room temperature. Protect from light. Close the bottle immediately after use. Do not use for longer than one month after opening the bottle.
Gatiflox
Gatifloxacin (Ophthalmic)
Gatiflox
Gatifloxacin (Ophthalmic)
Indications
Inflammation of the cornea
Indication detailsView
Gatifloxacin eye drops is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:
- Aerobic Gram-Positive Bacteria: Corynebacterium propinquum, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mitis, Streptococcus pneumoniae
- Aerobic Gram-Negative Bacteria: Haemophilus influenzae.
Therapeutic classView
Ophthalmic antibacterial drugs
PharmacologyView
The antibacterial action of gatifloxacin results from inhibition of DNA gyrase and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division. The mechanism of action of fluoroquinolones including gatifloxacin is different from that of aminoglycoside, macrolide, and tetracycline antibiotics. Therefore, gatifloxacin may be active against pathogens that are resistant to these antibiotics and these antibiotics may be active against pathogens that are resistant to gatifloxacin. There is no crossresistance between gatifloxacin and the aforementioned classes of antibiotics. Cross resistance has been observed between systemic gatifloxacin and some other fluoroquinolones. Resistance to gatifloxacin in vitro develops via multiple-step mutations.
DosageView
0.3% eye drops-
The recommended dosage regimen for the treatment of bacterial conjunctivitis is:- Days 1 and 2: Instill one drop every two hours in the affected eye(s) while awake, up to 8 times daily.
- Days 3 through 7: Instill one drop up to 4 times daily while awake.
0.5% eye drops-
Patients 1 year of age or older: Instill one drop every two hours in the affected eye(s) while awake, up to 8 times on Day 1. Instill one drop two to four times daily in the affected eye(s) while awake on Days 2 through 7.Side effectsView
The most frequently reported adverse events in the overall study population were conjunctival irritation, increased lacrimation etc.
ContraindicationsView
Gatifloxacin eye drops is contraindicated in patients with a history of hypersensitivity to Gatifloxacin, to other quinolones, or to any of the components in this medication. Gatiflox 0.3% eye drops should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye.
PrecautionsView
Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial conjunctivitis. Avoid contaminating the applicator tip with material from the eye, fingers or other source.
InteractionsView
Specific drug interaction studies have not been conducted with gatifloxacin eye drops. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.
Pregnancy & lactationView
Pregnancy Category C. Because there are no adequate and well-controlled studies in pregnant women, Gatifloxacin 0.3% eye drops should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Gatifloxacin is administered to a nursing woman.
Lactation: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Gatifloxacin is administered to a nursing woman.
Pediatric usageView
Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger patients.
Overdose effectsView
An overdose of this medication is unlikely to threaten life.
StorageView
Store in a cool and dry place, away from light. Keep out of reach of children.
Gatiflox ES
Gatifloxacin (Ophthalmic)
Gatiflox ES
Gatifloxacin (Ophthalmic)
Indications
Inflammation of the cornea
Indication detailsView
Gatifloxacin eye drops is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:
- Aerobic Gram-Positive Bacteria: Corynebacterium propinquum, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mitis, Streptococcus pneumoniae
- Aerobic Gram-Negative Bacteria: Haemophilus influenzae.
Therapeutic classView
Ophthalmic antibacterial drugs
PharmacologyView
The antibacterial action of gatifloxacin results from inhibition of DNA gyrase and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division. The mechanism of action of fluoroquinolones including gatifloxacin is different from that of aminoglycoside, macrolide, and tetracycline antibiotics. Therefore, gatifloxacin may be active against pathogens that are resistant to these antibiotics and these antibiotics may be active against pathogens that are resistant to gatifloxacin. There is no crossresistance between gatifloxacin and the aforementioned classes of antibiotics. Cross resistance has been observed between systemic gatifloxacin and some other fluoroquinolones. Resistance to gatifloxacin in vitro develops via multiple-step mutations.
DosageView
0.3% eye drops-
The recommended dosage regimen for the treatment of bacterial conjunctivitis is:- Days 1 and 2: Instill one drop every two hours in the affected eye(s) while awake, up to 8 times daily.
- Days 3 through 7: Instill one drop up to 4 times daily while awake.
0.5% eye drops-
Patients 1 year of age or older: Instill one drop every two hours in the affected eye(s) while awake, up to 8 times on Day 1. Instill one drop two to four times daily in the affected eye(s) while awake on Days 2 through 7.Side effectsView
The most frequently reported adverse events in the overall study population were conjunctival irritation, increased lacrimation etc.
ContraindicationsView
Gatifloxacin eye drops is contraindicated in patients with a history of hypersensitivity to Gatifloxacin, to other quinolones, or to any of the components in this medication. Gatiflox 0.3% eye drops should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye.
PrecautionsView
Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial conjunctivitis. Avoid contaminating the applicator tip with material from the eye, fingers or other source.
InteractionsView
Specific drug interaction studies have not been conducted with gatifloxacin eye drops. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.
Pregnancy & lactationView
Pregnancy Category C. Because there are no adequate and well-controlled studies in pregnant women, Gatifloxacin 0.3% eye drops should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Gatifloxacin is administered to a nursing woman.
Lactation: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Gatifloxacin is administered to a nursing woman.
Pediatric usageView
Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger patients.
Overdose effectsView
An overdose of this medication is unlikely to threaten life.
StorageView
Store in a cool and dry place, away from light. Keep out of reach of children.
Gatigen
Gatifloxacin (Ophthalmic)
Gatigen
Gatifloxacin (Ophthalmic)
Indications
Inflammation of the cornea
Indication detailsView
Gatifloxacin eye drops is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:
- Aerobic Gram-Positive Bacteria: Corynebacterium propinquum, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mitis, Streptococcus pneumoniae
- Aerobic Gram-Negative Bacteria: Haemophilus influenzae.
Therapeutic classView
Ophthalmic antibacterial drugs
PharmacologyView
The antibacterial action of gatifloxacin results from inhibition of DNA gyrase and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division. The mechanism of action of fluoroquinolones including gatifloxacin is different from that of aminoglycoside, macrolide, and tetracycline antibiotics. Therefore, gatifloxacin may be active against pathogens that are resistant to these antibiotics and these antibiotics may be active against pathogens that are resistant to gatifloxacin. There is no crossresistance between gatifloxacin and the aforementioned classes of antibiotics. Cross resistance has been observed between systemic gatifloxacin and some other fluoroquinolones. Resistance to gatifloxacin in vitro develops via multiple-step mutations.
DosageView
0.3% eye drops-
The recommended dosage regimen for the treatment of bacterial conjunctivitis is:- Days 1 and 2: Instill one drop every two hours in the affected eye(s) while awake, up to 8 times daily.
- Days 3 through 7: Instill one drop up to 4 times daily while awake.
0.5% eye drops-
Patients 1 year of age or older: Instill one drop every two hours in the affected eye(s) while awake, up to 8 times on Day 1. Instill one drop two to four times daily in the affected eye(s) while awake on Days 2 through 7.Side effectsView
The most frequently reported adverse events in the overall study population were conjunctival irritation, increased lacrimation etc.
ContraindicationsView
Gatifloxacin eye drops is contraindicated in patients with a history of hypersensitivity to Gatifloxacin, to other quinolones, or to any of the components in this medication. Gatiflox 0.3% eye drops should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye.
PrecautionsView
Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial conjunctivitis. Avoid contaminating the applicator tip with material from the eye, fingers or other source.
InteractionsView
Specific drug interaction studies have not been conducted with gatifloxacin eye drops. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.
Pregnancy & lactationView
Pregnancy Category C. Because there are no adequate and well-controlled studies in pregnant women, Gatifloxacin 0.3% eye drops should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Gatifloxacin is administered to a nursing woman.
Lactation: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Gatifloxacin is administered to a nursing woman.
Pediatric usageView
Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger patients.
Overdose effectsView
An overdose of this medication is unlikely to threaten life.
StorageView
Store in a cool and dry place, away from light. Keep out of reach of children.
Gatimet
Gatifloxacin (Oral)
Gatimet
Gatifloxacin (Oral)
Indications
Urinary tract infection
Indication detailsView
Gatifloxacin is indicated in the following infections:
- Acute bacterial exacerbation of chronic bronchitis due to Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Staphylococcus aureus.
- Acute sinusitis due to Streptococcus pneumoniae or Haemophilus influenzae.
- Community-acquired pneumonia due to Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Staphylococcus aureus, Mycoplasma pneumoniae, Chlamydia pneumoniae, or Legionella pneumophila.
- Uncomplicated skin and skin structure infections (i.e., simple abscesses, furuncles, folliculitis, wound infections, and cellulitis) due to Staphylococcus aureus or Streptococcus pyogenes.
- Uncomplicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis.
- Complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis.
- Pyelonephritis due to Escherichia coli.
- Uncomplicated urethral and cervical gonorrhea due to Neisseria gonorrhoeae.
- Acute, uncomplicated rectal infections in women due to Neisseria gonorrhoeae.
Therapeutic classView
4-Quinolone preparations
PharmacologyView
Gatifloxacin is a fluoroquinolone antibacterial which acts by inhibiting DNA synthesis in susceptible organisms via inhibition of both DNA gyrase (essential for bacterial reproduction) and topoisomerase IV (essential during bacterial cell division).
DosageView
- Acute Bacterial Exacerbation of Chronic Bronchitis: 400 mg 5 days
- Acute Sinusitis: 400 mg 10 days
- Community-acquired Pneumonia: 400 mg 7-14 days
- Uncomplicated Skin and Skin Structure Infections: 400 mg 7-10 days
- Uncomplicated Urinary Tract Infections: 400 mg Single Dose or 200 mg 3 days
- Complicated Urinary Tract Infections: 400 mg 7-10 days
- Acute Pyelonephritis: 400 mg 7-10 days
- Uncomplicated Urethral Gonnorrhea in Men: 400 mg Single dose
AdministrationView
Gatifloxacin can be administered without regard to food.
Side effectsView
Gatifloxacin is generally well tolerated. The most common side effects that can occur while taking this drug are usually mild and include nausea, vomiting, stomach pain, diarrhea, dizziness,and headache .
ContraindicationsView
Gatifloxacin is contraindicated in patients with a history of hypersensitivity of Gatifloxacin, quinolone antimicrobial agents, or any other components of this product.
PrecautionsView
Gatifloxacin should be administered with caution in the presence of renal insufficiency.
Pregnancy & lactationView
Pregnancy: Gatifloxacin should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus.
Lactation: It is not known whether Gatifloxacin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when gatifloxacin is administered to a nursing woman.
Lactation: It is not known whether Gatifloxacin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when gatifloxacin is administered to a nursing woman.
Pediatric usageView
Renal Impaired patient:
- Creatinine Clearance 40 mL/min: 400 mg every day.
- Creatinine Clearance < 40 mL/min: 400 mg 200 mg every day.
- Hemodialysis: 400 mg 200 mg every day.
- Continuous peritoneal dialysis: 400 mg 200 mg every day.
Overdose effectsView
Gatifloxacin exhibits a low potential for acute toxicity in animal studies. In the event of acute oral overdose, the stomach should be emptied by inducing vomiting or by gastric lavage. The patient should be carefully observed (including ECG monitoring) and given symptomatic and supportive treatment. Adequate hydration should be maintained.
Gatinox
Gatifloxacin (Oral)
Gatinox
Gatifloxacin (Oral)
Indications
Urinary tract infection
Indication detailsView
Gatifloxacin is indicated in the following infections:
- Acute bacterial exacerbation of chronic bronchitis due to Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Staphylococcus aureus.
- Acute sinusitis due to Streptococcus pneumoniae or Haemophilus influenzae.
- Community-acquired pneumonia due to Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Staphylococcus aureus, Mycoplasma pneumoniae, Chlamydia pneumoniae, or Legionella pneumophila.
- Uncomplicated skin and skin structure infections (i.e., simple abscesses, furuncles, folliculitis, wound infections, and cellulitis) due to Staphylococcus aureus or Streptococcus pyogenes.
- Uncomplicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis.
- Complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis.
- Pyelonephritis due to Escherichia coli.
- Uncomplicated urethral and cervical gonorrhea due to Neisseria gonorrhoeae.
- Acute, uncomplicated rectal infections in women due to Neisseria gonorrhoeae.
Therapeutic classView
4-Quinolone preparations
PharmacologyView
Gatifloxacin is a fluoroquinolone antibacterial which acts by inhibiting DNA synthesis in susceptible organisms via inhibition of both DNA gyrase (essential for bacterial reproduction) and topoisomerase IV (essential during bacterial cell division).
DosageView
- Acute Bacterial Exacerbation of Chronic Bronchitis: 400 mg 5 days
- Acute Sinusitis: 400 mg 10 days
- Community-acquired Pneumonia: 400 mg 7-14 days
- Uncomplicated Skin and Skin Structure Infections: 400 mg 7-10 days
- Uncomplicated Urinary Tract Infections: 400 mg Single Dose or 200 mg 3 days
- Complicated Urinary Tract Infections: 400 mg 7-10 days
- Acute Pyelonephritis: 400 mg 7-10 days
- Uncomplicated Urethral Gonnorrhea in Men: 400 mg Single dose
AdministrationView
Gatifloxacin can be administered without regard to food.
Side effectsView
Gatifloxacin is generally well tolerated. The most common side effects that can occur while taking this drug are usually mild and include nausea, vomiting, stomach pain, diarrhea, dizziness,and headache .
ContraindicationsView
Gatifloxacin is contraindicated in patients with a history of hypersensitivity of Gatifloxacin, quinolone antimicrobial agents, or any other components of this product.
PrecautionsView
Gatifloxacin should be administered with caution in the presence of renal insufficiency.
Pregnancy & lactationView
Pregnancy: Gatifloxacin should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus.
Lactation: It is not known whether Gatifloxacin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when gatifloxacin is administered to a nursing woman.
Lactation: It is not known whether Gatifloxacin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when gatifloxacin is administered to a nursing woman.
Pediatric usageView
Renal Impaired patient:
- Creatinine Clearance 40 mL/min: 400 mg every day.
- Creatinine Clearance < 40 mL/min: 400 mg 200 mg every day.
- Hemodialysis: 400 mg 200 mg every day.
- Continuous peritoneal dialysis: 400 mg 200 mg every day.
Overdose effectsView
Gatifloxacin exhibits a low potential for acute toxicity in animal studies. In the event of acute oral overdose, the stomach should be emptied by inducing vomiting or by gastric lavage. The patient should be carefully observed (including ECG monitoring) and given symptomatic and supportive treatment. Adequate hydration should be maintained.
Gatipro
Gatifloxacin (Ophthalmic)
Gatipro
Gatifloxacin (Ophthalmic)
Indications
Inflammation of the cornea
Indication detailsView
Gatifloxacin eye drops is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:
- Aerobic Gram-Positive Bacteria: Corynebacterium propinquum, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mitis, Streptococcus pneumoniae
- Aerobic Gram-Negative Bacteria: Haemophilus influenzae.
Therapeutic classView
Ophthalmic antibacterial drugs
PharmacologyView
The antibacterial action of gatifloxacin results from inhibition of DNA gyrase and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division. The mechanism of action of fluoroquinolones including gatifloxacin is different from that of aminoglycoside, macrolide, and tetracycline antibiotics. Therefore, gatifloxacin may be active against pathogens that are resistant to these antibiotics and these antibiotics may be active against pathogens that are resistant to gatifloxacin. There is no crossresistance between gatifloxacin and the aforementioned classes of antibiotics. Cross resistance has been observed between systemic gatifloxacin and some other fluoroquinolones. Resistance to gatifloxacin in vitro develops via multiple-step mutations.
DosageView
0.3% eye drops-
The recommended dosage regimen for the treatment of bacterial conjunctivitis is:- Days 1 and 2: Instill one drop every two hours in the affected eye(s) while awake, up to 8 times daily.
- Days 3 through 7: Instill one drop up to 4 times daily while awake.
0.5% eye drops-
Patients 1 year of age or older: Instill one drop every two hours in the affected eye(s) while awake, up to 8 times on Day 1. Instill one drop two to four times daily in the affected eye(s) while awake on Days 2 through 7.Side effectsView
The most frequently reported adverse events in the overall study population were conjunctival irritation, increased lacrimation etc.
ContraindicationsView
Gatifloxacin eye drops is contraindicated in patients with a history of hypersensitivity to Gatifloxacin, to other quinolones, or to any of the components in this medication. Gatiflox 0.3% eye drops should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye.
PrecautionsView
Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial conjunctivitis. Avoid contaminating the applicator tip with material from the eye, fingers or other source.
InteractionsView
Specific drug interaction studies have not been conducted with gatifloxacin eye drops. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.
Pregnancy & lactationView
Pregnancy Category C. Because there are no adequate and well-controlled studies in pregnant women, Gatifloxacin 0.3% eye drops should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Gatifloxacin is administered to a nursing woman.
Lactation: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Gatifloxacin is administered to a nursing woman.
Pediatric usageView
Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger patients.
Overdose effectsView
An overdose of this medication is unlikely to threaten life.
StorageView
Store in a cool and dry place, away from light. Keep out of reach of children.
Gatipro
Gatifloxacin (Ophthalmic)
Gatipro
Gatifloxacin (Ophthalmic)
Indications
Inflammation of the cornea
Indication detailsView
Gatifloxacin eye drops is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:
- Aerobic Gram-Positive Bacteria: Corynebacterium propinquum, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mitis, Streptococcus pneumoniae
- Aerobic Gram-Negative Bacteria: Haemophilus influenzae.
Therapeutic classView
Ophthalmic antibacterial drugs
PharmacologyView
The antibacterial action of gatifloxacin results from inhibition of DNA gyrase and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division. The mechanism of action of fluoroquinolones including gatifloxacin is different from that of aminoglycoside, macrolide, and tetracycline antibiotics. Therefore, gatifloxacin may be active against pathogens that are resistant to these antibiotics and these antibiotics may be active against pathogens that are resistant to gatifloxacin. There is no crossresistance between gatifloxacin and the aforementioned classes of antibiotics. Cross resistance has been observed between systemic gatifloxacin and some other fluoroquinolones. Resistance to gatifloxacin in vitro develops via multiple-step mutations.
DosageView
0.3% eye drops-
The recommended dosage regimen for the treatment of bacterial conjunctivitis is:- Days 1 and 2: Instill one drop every two hours in the affected eye(s) while awake, up to 8 times daily.
- Days 3 through 7: Instill one drop up to 4 times daily while awake.
0.5% eye drops-
Patients 1 year of age or older: Instill one drop every two hours in the affected eye(s) while awake, up to 8 times on Day 1. Instill one drop two to four times daily in the affected eye(s) while awake on Days 2 through 7.Side effectsView
The most frequently reported adverse events in the overall study population were conjunctival irritation, increased lacrimation etc.
ContraindicationsView
Gatifloxacin eye drops is contraindicated in patients with a history of hypersensitivity to Gatifloxacin, to other quinolones, or to any of the components in this medication. Gatiflox 0.3% eye drops should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye.
PrecautionsView
Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial conjunctivitis. Avoid contaminating the applicator tip with material from the eye, fingers or other source.
InteractionsView
Specific drug interaction studies have not been conducted with gatifloxacin eye drops. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.
Pregnancy & lactationView
Pregnancy Category C. Because there are no adequate and well-controlled studies in pregnant women, Gatifloxacin 0.3% eye drops should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Gatifloxacin is administered to a nursing woman.
Lactation: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Gatifloxacin is administered to a nursing woman.
Pediatric usageView
Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger patients.
Overdose effectsView
An overdose of this medication is unlikely to threaten life.
StorageView
Store in a cool and dry place, away from light. Keep out of reach of children.
Gatison
Gatifloxacin + Dexamethasone
Gatison
Gatifloxacin + Dexamethasone
Indications
Steroid-responsive inflammatory ocular conditions
Indication detailsView
This Sterile Eye Drops is indicated for steroid responsive ocular inflammatory conditions with involvement of bacteria like blepharitis, scleritis, episcleritis, iritis, cyclitis, iridocyclitis, choroiditis, optic neuritis and chronic anterior uveitis, disciform and interstitial keratitis, allergic corneal marginal ulcers, corneal injury from chemical radiation or thermal burns.
Therapeutic classView
Ophthalmic steroid - antibiotic combined preparations
PharmacologyView
Dexamethasone is a synthetic glucocorticoid which decreases inflammation by inhibiting the migration of leukocytes and reversal of increased capillary permeability. It suppresses normal immune response.
Gatifloxacin inhibits bacterial DNA gyrase and Topoisomerase IV, the enzymes responsible for replication, transcription and repair of bacterial DNA.
Gatifloxacin inhibits bacterial DNA gyrase and Topoisomerase IV, the enzymes responsible for replication, transcription and repair of bacterial DNA.
DosageView
Instill 1-2 drops into the conjunctival sac 3 to 4 times daily.
Side effectsView
Mild burning, chemosis, redness may occur.
ContraindicationsView
This is contraindicated in epithelial herpes simplex keratitis (Dendritic keratitis), vaccinia, varicella, and in many other viral diseases of the conjunctiva and cornea. It is also contraindicated in mycobacterial infection of the eye, fungal diseases of ocular structures and in individuals hypersensitive to any of the components of the medication.
PrecautionsView
For ophthalmic use only. If the product is used for 10 days or more, intraocular pressure should be monitored routinely.
Pregnancy & lactationView
Use in pregnancy: There are no adequate and well-controlled studies in pregnant women. Gatifloxacin + Dexamethasone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Use in lactation: Caution should be exercised when Gatifloxacin + Dexamethasone is administered to a nursing mother.
Use in lactation: Caution should be exercised when Gatifloxacin + Dexamethasone is administered to a nursing mother.
Pediatric usageView
Use in children: Safety and effectiveness in pediatric patients have not been established.
Overdose effectsView
Overdose through local administration is not known. In case of accidental oral intake, specific measures to reduce resorption should be taken. There is no specific antidote.
StorageView
Store at room temperature. Protect from light. Close the bottle immediately after use. Do not use for longer than one month after opening the bottle.